Ratings Cigna

Equities

CI

US1255231003

Market Closed - Nyse Other stock markets 04:00:02 2024-05-09 pm EDT			5-day change	1st Jan Change
351 ^USD	+1.04%		+1.88%	+17.20%

May. 06	UBS Adjusts Cigna Price Target to $410 From $400, Maintains Buy Rating	MT
May. 06	Jefferies Adjusts Price Target on Cigna to $407 From $385, Keeps Buy Rating	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

The stock, which is currently worth 2024 to 0.51 times its sales, is clearly overvalued in comparison with peers.
The company has a low valuation given the cash flows generated by its activity.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company does not generate enough profits, which is an alarming weak point.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
CIGNA	+17.20%	98.67B	B-
UNITEDHEALTH GROUP INC.	-3.69%	463B	B-
CENTENE CORPORATION	+4.64%	40.48B	B-
HUMANA INC.	-26.90%	39.06B	A-
MOLINA HEALTHCARE, INC.	-3.12%	20.18B	B-
PROGYNY, INC.	-12.59%	3.09B	C+
ALIGNMENT HEALTHCARE, INC.	-19.74%	1.3B	B-
CLOVER HEALTH INVESTMENTS, CORP.	-9.33%	432M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes